Telomerase Cajal body protein 1 depletion inhibits telomerase trafficking to telomeres and induces G1 cell cycle arrest in A549 cells

Yuan,Ping; Wang,Zhitian; Lv,Wang; Pan,Hui; Yang,Yunhai; Yuan,Xiaoshuai; Hu,Jian

doi:10.3892/ol.2014.2306

Telomerase Cajal body protein 1 depletion inhibits telomerase trafficking to telomeres and induces G1 cell cycle arrest in A549 cells

Authors:
- Ping Yuan
- Zhitian Wang
- Wang Lv
- Hui Pan
- Yunhai Yang
- Xiaoshuai Yuan
- Jian Hu
View Affiliations

Affiliations: Department of Thoracic Surgery, First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
Published online on: July 2, 2014 https://doi.org/10.3892/ol.2014.2306
Pages: 1009-1016

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Telomerase Cajal body protein 1 (TCAB1) is a telomerase holoenzyme, which is markedly enriched in Cajal bodies (CBs) and facilitates the recruitment of telomerase to CBs in the S phase of the cell cycle. This recruitment is dependent on TCAB1 binding to a telomerase RNA component. The majority of cancer cells are able to grow indefinitely due to telomerase and its mechanism of trafficking to telomeres. In the present study, a certain level of TCAB1 expression in A549 human lung cells was identified and TCAB1 knockdown exhibited a potent antiproliferative effect on these cells, which was coupled with a decrease in the cell density and activity of the cellular enzymes. In addition, TCAB1‑depletion was demonstrated to inhibit telomerase trafficking to telomeres in the A549 cells, leading to subsequent G1 cell cycle arrest without inducing apoptotic cell death. Overall, these observations indicated that TCAB1 may be essential for A549 cell proliferation and cell cycle regulation, and may be a potential candidate for the development of a therapeutic target for lung adenocarcinomas.

View Figures

View References

1	Greider CW and Blackburn EH: Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 43:405–413. 1985.
2	Shay JW and Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer. 33:787–791. 1997.
3	Cui W, Wylie D, Aslam S, et al: Telomerase-immortalized sheep fibroblasts can be reprogrammed by nuclear transfer to undergo early development. Biol Reprod. 69:15–21. 2003.
4	Bolzán AD: Chromosomal aberrations involving telomeres and interstitial telomeric sequences. Mutagenesis. 27:1–15. 2012.
5	Granger MP, Wright WE and Shay JW: Telomerase in cancer and aging. Crit Rev Oncol Hematol. 41:29–40. 2002.
6	Hoos A, Hepp HH, Kaul S, Ahlert T, Bastert G and Wallwiener D: Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer. Int J Cancer. 79:8–12. 1998.
7	Yashima K, Milchgrub S, Gollahon LS, et al: Telomerase enzyme activity and RNA expression during the multistage pathogenesis of breast carcinoma. Clin Cancer Res. 4:229–234. 1998.
8	Mokbel K and Williams NJ: Telomerase and breast cancer: from diagnosis to therapy. Int J Surg Investig. 2:85–88. 2000.
9	Feng J, Funk WD, Wang SS, et al: The RNA component of human telomerase. Science. 269:1236–1241. 1995.
10	Cech TR, Nakamura TM and Lingner J: Telomerase is a true reverse transcriptase. A review. Biochemistry (Mosc). 62:1202–1205. 1997.
11	Avilion AA, Piatyszek MA, Gupta J, Shay JW, Bacchetti S and Greider CW: Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res. 56:645–650. 1996.
12	Ito H, Kyo S, Kanaya T, Takakura M, Inoue M and Namiki M: Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. Clin Cancer Res. 4:1603–1608. 1998.
13	Kyo S, Kanaya T, Takakura M, Tanaka M and Inoue M: Human telomerase reverse transcriptase as a critical determinant of telomerase activity in normal and malignant endometrial tissues. Int J Cancer. 80:60–63. 1999.
14	Cristofari G, Adolf E, Reichenbach P, et al: Human telomerase RNA accumulation in Cajal bodies facilitates telomerase recruitment to telomeres and telomere elongation. Mol Cell. 27:882–889. 2007.
15	Zhu Y, Tomlinson RL, Lukowiak AA, Terns RM and Terns MP: Telomerase RNA accumulates in Cajal bodies in human cancer cells. Mol Biol Cell. 15:81–90. 2004.
16	Tomlinson RL, Abreu EB, Ziegler T, et al: Telomerase reverse transcriptase is required for the localization of telomerase RNA to cajal bodies and telomeres in human cancer cells. Mol Biol Cell. 19:3793–3800. 2008.
17	Arnoult N, Schluth-Bolard C, Letessier A, et al: Replication timing of human telomeres is chromosome arm-specific, influenced by subtelomeric structures and connected to nuclear localization. PLoS Genet. 6:e10009202010.
18	Mahmoudi S, Henriksson S, Weibrecht I, et al: WRAP53 is essential for Cajal body formation and for targeting the survival of motor neuron complex to Cajal bodies. PLoS Biol. 8:e10005212010.
19	Tycowski KT, Shu MD, Kukoyi A and Steitz JA: A conserved WD40 protein binds the Cajal body localization signal of scaRNP particles. Mol Cell. 34:47–57. 2009.
20	Venteicher AS, Abreu EB, Meng Z, et al: A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science. 323:644–648. 2009.
21	Egan ED and Collins K: An enhanced H/ACA RNP assembly mechanism for human telomerase RNA. Mol Cell Biol. 32:2428–2439. 2012.
22	Smogorzewska A, van Steensel B, Bianchi A, et al: Control of human telomere length by TRF1 and TRF2. Mol Cell Biol. 20:1659–1668. 2000.
23	Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med. 359:1367–1380. 2008.
24	Helmstetter CE: DNA synthesis during the division cycle of rapidly growing Escherichia coli B/r. J Mol Biol. 31:507–518. 1968.
25	Hu J, Hwang SS, Liesa M, et al: Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell. 148:651–663. 2012.
26	Henson JD, Neumann AA, Yeager TR and Reddel RR: Alternative lengthening of telomeres in mammalian cells. Oncogene. 21:598–610. 2002.
27	Slatter TL, Tan X, Yuen YC, et al: The alternative lengthening of telomeres pathway may operate in non-neoplastic human cells. J Pathol. 226:509–518. 2012.
28	Lundblad V and Blackburn EH: An alternative pathway for yeast telomere maintenance rescues est1-senescence. Cell. 73:347–360. 1993.
29	Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA and Reddel RR: Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med. 3:1271–1274. 1997.
30	Pajalunga D, Mazzola A, Franchitto A, Puggioni E and Crescenzi M: The logic and regulation of cell cycle exit and reentry. Cell Mol Life Sci. 65:8–15. 2008.
31	Cesare AJ and Karlseder J: A three-state model of telomere control over human proliferative boundaries. Curr Opin Cell Biol. 24:731–738. 2012.
32	Verdun RE and Karlseder J: The DNA damage machinery and homologous recombination pathway act consecutively to protect human telomeres. Cell. 127:709–720. 2006.
33	Stern JL, Zyner KG, Pickett HA, Cohen SB and Bryan TM: Telomerase recruitment requires both TCAB1 and Cajal bodies independently. Mol Cell Biol. 32:2384–2395. 2012.
34	Zhong FL, Batista LF, Freund A, Pech MF, Venteicher AS and Artandi SE: TPP1 OB-fold domain controls telomere maintenance by recruiting telomerase to chromosome ends. Cell. 150:481–494. 2012.
35	Schildkraut JM, Goode EL, Clyde MA, et al: Australian Ovarian Cancer Study Group: Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res. 69:2349–2357. 2009.